ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 8, 2021

10:45AM-11:00AM: Abstract Number: 1431

Human TLR8 Leads to Fatal Anemia Due to Ineffective Erythropoiesis in Bone Marrow Erythroblastic Islands in Murine SLE

Abstracts: Innate Immunity (1430–1433)

10:45AM-11:00AM: Abstract Number: 1435

Identification of Distinct Fibroblast Populations in Systemic Sclerosis 3D Skin Tissues with Single Cell Omics

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science (1434–1437)

10:45AM-11:00AM: Abstract Number: 1425

Voclosporin for Lupus Nephritis: Interim Analysis of the AURORA 2 Extension Study

Plenary III (1424–1429)

11:00AM-11:15AM: Abstract Number: 1436

Expanded PD-1hi CXCR5- HLA-DR+ T Cells Is Associated with Interstitial Lung Disease in Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science (1434–1437)

11:00AM-11:15AM: Abstract Number: 1426

Genotype and Transfusion Dependence Predicts Mortality in VEXAS Syndrome, a Newly Described Disease with Overlap Inflammatory and Hematologic Features

Plenary III (1424–1429)

11:00AM-11:15AM: Abstract Number: 1432

Modulation of Auto-Inflammation with a Novel Selective Cyclic GMP-AMP Synthase (cGAS) Inhibitor in a Trex1-/- Model

Abstracts: Innate Immunity (1430–1433)

11:15AM-11:30AM: Abstract Number: 1433

Endothelium-protective, Histone-neutralizing Properties of the Polyanionic Agent Defibrotide

Abstracts: Innate Immunity (1430–1433)

11:15AM-11:30AM: Abstract Number: 1437

Fat and Fibrosis: A Novel Developmental Gene in Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science (1434–1437)

11:15AM-11:30AM: Abstract Number: 1427

Reduction of Cardiovascular Disease and Mortality versus Risk of New Onset Diabetes with Statin Use in Patients with Rheumatoid Arthritis

Plenary III (1424–1429)

11:30AM-11:45AM: Abstract Number: 1428

Association Between Ongoing Glucocorticoid Use and Major Adverse Cardiovascular Events Among Veterans with Rheumatoid Arthritis

Plenary III (1424–1429)

11:45AM-12:00PM: Abstract Number: 1429

ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Diseases

Plenary III (1424–1429)

2:00PM-2:15PM: Abstract Number: 1438

Development of a Computationally Designed, Hyperstable Dual Inhibitor of the IL-2 and IL-15 Receptors: A Novel Therapeutic Candidate for Inflammatory Conditions

Abstracts: Cytokines & Cell Trafficking (1438–1441)

2:00PM-2:15PM: Abstract Number: 1442

Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)

Abstracts: RA – Treatments II: New Findings in Established Therapies (1442–1445)

2:00PM-2:15PM: Abstract Number: 1446

Trauma Is Associated with Flares in Systemic Lupus Erythematosus (SLE)

Abstracts: Clinical Epidemiology (1446–1451)

2:15PM-2:30PM: Abstract Number: 1439

Inhibitors of Endogenous Reverse Transcriptases Suppress in Vitro Type I Interferon Responses and in Vivo Antigen-specific T Cell Responses

Abstracts: Cytokines & Cell Trafficking (1438–1441)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].